Description
Identification of therapeutically relevant gene mutations for Myeloid cancerCancer
OncQuer(TM) CML panel
Identification of therapeutically relevant gene mutations for Myeloid cancerCancer
TAT:
Specimen Type:
Genomics Panel Test
Other Tests
-
264%
OncQuer TM Scout LB EGFR Sensitivity Test
Identification gene mutations leading to sensitivity to EGFR therapy
OncQuer TM Scout LB EGFR Sensitivity Test
Identification gene mutations leading to sensitivity to EGFR therapy
-
264%
Oncoprint
Hotspot genes: ABL1, BRAF, CBL, CSF3R, DNMT3A, FLT3, GATA2, HRAS, IDH1, IDH2, JAK2, KIT, KRAS, MPL, MYD88, NPM1, NRAS, PTPN11, SETBP1, SF3B1, SRSF2, U2AF1, WT1. Full Genes: ASXL1, BCOR, CALR, CEBPA, ETV6, EZH2, IKZF1, NF1, PHF6, PRPF8, RB1, RUNX1, SH2B3, STAG2, TET2, TP53, ZRSR2. Fusion Driver Genes: ABL1, ALK, BCL2, BRAF, CCND1, CREBBP, EGFR, ETV6 (TEL), FGFR1, FGFR2, FUS, HMGA2, JAK2, KMT2A(MLL), MECOM, MET, MLLT10, MLLT3, MYBL1, MYH11, NTRK3, NUP214, PDGFRA, PDGFRB, RARA, RBM16, RUNX1 (AML1), TCF3(E2A), TFE3
Oncoprint
Hotspot genes: ABL1, BRAF, CBL, CSF3R, DNMT3A, FLT3, GATA2, HRAS, IDH1, IDH2, JAK2, KIT, KRAS, MPL, MYD88, NPM1, NRAS, PTPN11, SETBP1, SF3B1, SRSF2, U2AF1, WT1. Full Genes: ASXL1, BCOR, CALR, CEBPA, ETV6, EZH2, IKZF1, NF1, PHF6, PRPF8, RB1, RUNX1, SH2B3, STAG2, TET2, TP53, ZRSR2. Fusion Driver Genes: ABL1, ALK, BCL2, BRAF, CCND1, CREBBP, EGFR, ETV6 (TEL), FGFR1, FGFR2, FUS, HMGA2, JAK2, KMT2A(MLL), MECOM, MET, MLLT10, MLLT3, MYBL1, MYH11, NTRK3, NUP214, PDGFRA, PDGFRB, RARA, RBM16, RUNX1 (AML1), TCF3(E2A), TFE3
-
264%
OncQuer TM Germline Mutation Panel by NGS
Identification of gene mutations that increase risk of cancer or has therapeutic implications in an affected individual
OncQuer TM Germline Mutation Panel by NGS
Identification of gene mutations that increase risk of cancer or has therapeutic implications in an affected individual
- 253%
Reviews
There are no reviews yet.